1-7 of 7
Erkut Borazanci
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)

Hani Babiker, Erkut Borazanci, Vivek Subbiah, Sanjiv Agarwala, Alain Algazi, Jacob Schachter, Michael Lotem, Corinne Maurice-Dror, Daniel Hendler, Shah Rahimian, Hans Minderman, Cara Haymaker, Daruka Mahadevan, Chantale Bernatchez, Ravi Murthy, Rolf Hultsch, Nadia Kaplan, Gregory Woodhead, Charles Hennemeyer, Srinivas Chunduru, Peter M. Anderson, Adi Diab, Igor Puzanov
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (23): 5079–5087.
https://doi.org/10.1158/1078-0432.CCR-21-4486
Published: 01 December 2022
View article titled, Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)
Open the PDF for Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101) in another window
Includes: Supplementary data
Journal Articles

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Pamela N. Munster, Andrew E. Greenstein, Gini F. Fleming, Erkut Borazanci, Manish R. Sharma, Joseph M. Custodio, Iulia Cristina Tudor, Hristina I. Pashova, Stacie Peacock Shepherd, Andreas Grauer, Jasgit C. Sachdev
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3214–3224.
https://doi.org/10.1158/1078-0432.CCR-21-4363
Published: 02 August 2022
View article titled, Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Open the PDF for Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers

Raju Kandimalla, Jianfeng Xu, Alexander Link, Takatoshi Matsuyama, Kensuke Yamamura, M. Iqbal Parker, Hiroyuki Uetake, Francesc Balaguer, Erkut Borazanci, Susan Tsai, Douglas Evans, Stephen J. Meltzer, Hideo Baba, Randall Brand, Daniel Von Hoff, Wei Li, Ajay Goel
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6135–6144.
https://doi.org/10.1158/1078-0432.CCR-21-1982
Published: 15 November 2021
View article titled, EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Open the PDF for EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers in another window
Includes: Supplementary data
Journal Articles

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Bruno Bockorny, Teresa Macarulla, Valerya Semenisty, Erkut Borazanci, Jaime Feliu, Mariano Ponz-Sarvise, David Gutierrez Abad, Paul Oberstein, Angela Alistar, Andres Muñoz, Ravit Geva, Carmen Guillén-Ponce, Mercedes Salgado Fernandez, Amnon Peled, Marya Chaney, Irit Gliko-Kabir, Liron Shemesh-Darvish, Debby Ickowicz, Ella Sorani, Shaul Kadosh, Abi Vainstein-Haras, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 5020–5027.
https://doi.org/10.1158/1078-0432.CCR-21-0929
Published: 15 September 2021
View article titled, Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Open the PDF for Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial in another window
Includes: Supplementary data
Journal Articles

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw, Ryohei Katayama, Yuki Shimizu, Viola W. Zhu, Thomas Yang Sun, Heather A. Wakelee, Russell Madison, Alexa B. Schrock, Giorgio Senaldi, Naoki Nakao, Hiroyuki Hanzawa, Masaya Tachibana, Takeshi Isoyama, Kenji Nakamaru, Chenhui Deng, Meijing Li, Frank Fan, Qinying Zhao, Yanfei Gao, Takashi Seto, Pasi A. Jänne, Sai-Hong Ignatius Ou
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (18): 4785–4794.
https://doi.org/10.1158/1078-0432.CCR-20-1630
Published: 15 September 2020
View article titled, U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

Dung T. Le, Vincent J. Picozzi, Andrew H. Ko, Zev A. Wainberg, Hedy Kindler, Andrea Wang-Gillam, Paul Oberstein, Michael A. Morse, Herbert J. Zeh, III, Colin Weekes, Tony Reid, Erkut Borazanci, Todd Crocenzi, Noelle K. LoConte, Benjamin Musher, Dan Laheru, Aimee Murphy, Chan Whiting, Nitya Nair, Amanda Enstrom, Sandy Ferber, Dirk G. Brockstedt, Elizabeth M. Jaffee
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5493–5502.
https://doi.org/10.1158/1078-0432.CCR-18-2992
Published: 13 September 2019
View article titled, Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Open the PDF for Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study) in another window
Includes: Supplementary data
Journal Articles

Pancreatic Cancer: “A Riddle Wrapped in a Mystery inside an Enigma”

Erkut Borazanci, Chi V. Dang, Robert W. Robey, Susan E. Bates, John A. Chabot, Daniel D. Von Hoff
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (7): 1629–1637.
https://doi.org/10.1158/1078-0432.CCR-16-2070
Published: 02 April 2017
View article titled, Pancreatic Cancer: “A Riddle Wrapped in a Mystery inside an Enigma”
Open the PDF for Pancreatic Cancer: “A Riddle Wrapped in a Mystery inside an Enigma” in another window